Exposure to the smoking cessation medicine varenicline during pregnancy: A prospective nationwide cohort study

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 10, 2013, Pages 1086-1092

  Harrison Woolrych, Mira ^a   Paterson, Helen ^b   Tan, Ming ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Pharmacoepidemiology; Pregnancy exposure; Smoking cessation; Varenicline

Indexed keywords

VARENICLINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANKYLOGLOSSIA; ARTICLE; CHEST INFECTION; COHORT ANALYSIS; CONCEPTION; DRUG UTILIZATION; FEEDING DIFFICULTY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; NEW ZEALAND; OBSERVATIONAL STUDY; PATIENT MONITORING; PERINATAL ASPHYXIA; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RECURRENT INFECTION; TREATMENT DURATION;

PHARMACOEPIDEMIOLOGY; PREGNANCY EXPOSURE; SMOKING CESSATION; VARENICLINE;

ADOLESCENT; ADULT; BENZAZEPINES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATERNAL EXPOSURE; MIDDLE AGED; NEW ZEALAND; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; QUESTIONNAIRES; QUINOXALINES; SMOKING CESSATION; TIME FACTORS;

EID: 84884985587     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3489     Document Type: Article

References (19)

1. Rodriguez-Thompson D. Smoking and pregnancy. Up-To-Date 2012. [http://www.uptodate.com/contents/smoking-and-pregnancy]. [November 2012].
2. ACOG. Committee opinion no. 471: smoking cessation during pregnancy. Obstet Gynaecol 2010; 116: 1241.
3. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359(19): 2018-2024.
4. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70(3): 801-805.
5. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 2004; 328(7438): 509-511.
6. FDA. Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm. Accessed 31 October 2012, 2012.
7. Pfizer. Chantix product labeling. http://www.pdr.net/drugpages/productlabeling.aspx?mpcode=62950550#section-9.2. Accessed February 2012, 2012. Accessed February 2012, 2012.
8. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166(15): 1571-1577.
9. Stack NM. Smoking cessation: an overview of treatment options with a focus on varenicline. Pharmacotherapy Nov 2007; 27(11): 1550-1557.
10. Pfizer. New Zealand data sheet for Champix. March 2011; http://www.medsafe.govt.nz/profs/datasheets. Accessed June 2011.
11. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In Pharmacovigilance (2nd edn), Mann R, Andrews EB (ed.). John Wiley and Sons Ltd: Chichester, 2007; 313-328.
12. Kunac DL, Harrison-Woolrych M, Tatley MV. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 3 Oct 2008; 121(1283): 76-89.
13. Harrison-Woolrych M, Ashton J. Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand. Pharmacoepidemiol Drug Saf 2010 Sep; 19(9): 949-953.
14. Rowlands S. Contraception and abortion. J R Soc Med 2007; 100: 465-468.
15. Ludford I, Scheil W, Tucker G, Grivell R. Pregnancy outcomes for nulliparous women of advanced maternal age in South Australia, 1998-2008. Aust N Z J Obstet Gynaecol 2012; 52(3): 235-241.
16. Maritz GS. Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring. Ther Adv Respir Dis 2009 Aug; 3(4): 193-210.
17. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatr 2008 Oct; 97(10): 1331-1337.
18. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006 Sep; 70(3): 801-805.
19. Schmitz M, Denardin D, Laufer Silva T, et al. Smoking during pregnancy and attention-deficit/hyperactivity disorder, predominantly inattentive type: a case-control study. J Am Acad Child Adolesc Psychiatry 2006 Nov; 45(11): 1338-1345.